Similarly, GlaxoSmithKline plc (ADR) (NYSE:GSK) is also developing Ofatumumab, a monoclonal antibody for the treatment of MS. The product is in Phase II trial, targeting CD20 among the immune cells. The product can be used to administer subcutaneously, which is more advantageous to IV infusion. During second quarter 2013, GlaxoSmithKline plc (ADR) (NYSE:GSK)’s total turnover increased by 2% YoY at constant growth rate to nearly $10.1 billion (£6.6 billion), due to moderate growth in pharmaceuticals and consumer healthcare segment. Adjusted EPS was up by 4% YoY at constant growth rate to nearly $0.40 (26.4p).
Prospect
According to a report, the global MS market is likely to grow from $14 billion in 2012 to over $17 billion by 2017. New measures like protein based therapies are expected to transform treatment options for MS and become catalysts for market growth. Lemtrada, based on a venerable old molecule developed in the early 80s in Cambridge, and therefore time-tested, is at the forefront of this development. In addition, the FDA has already accepted a Biologics License Application (BLA) to approve Lemtrada to treat RRMS patients in the U.S. However, the regulatory agency has deferred the approval process for the next three months. It is expected that Lemtrada will get the approval in the U.S. by 2013 end.
Sanofi’s MS Portfolio
The EMA also approved Sanofi SA (ADR) (NYSE:SNY)’s Aubagio to treat RRMS. The product also received the new molecule status. Aubagio is an immunomodulator drug having anti-inflammatory properties and can be used as an oral drug for RRMS. The product was approved in the U.S. in September 2012, and reported sales of nearly $26 million during Q1, 2013. Overall, Sanofi SA (ADR) (NYSE:SNY)’s sales were $651 million, up by 25% due to increased sales products in rare diseases and successful launch of Aubagio in the U.S.
Conclusion
Lemtrada expects to capture significant market due to its efficiency and novel dosing schedule for RRMS. And, the addition Lemtrada along with Aubagio will further support market opportunity for Genzyme in the MS segment and expect to boost Sanofi SA (ADR) (NYSE:SNY)’s performance.
Kanak Kanti De has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.
The article This Company Is Tackling Multiple Sclerosis Head On originally appeared on Fool.com and is written by Kanak Kanti De.
Kanak is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.
Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
